• 1
    LeRoy EC. Increased collagen synthesis by scleroderma skin fibroblasts in vitro: a possible defect in the regulation or activation of the scleroderma fibroblast. J Clin Invest 1974; 54: 8809.
  • 2
    Jimenez SA, Hitraya E, Varga J. Pathogenesis of scleroderma: collagen [review]. Rheum Dis Clin North Am 1996; 22: 64774.
  • 3
    Strehlow D, Korn JH. Biology of the scleroderma fibroblast [review]. Curr Opin Rheumatol 1998; 10: 5728.
  • 4
    Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 55767.
  • 5
    Derk CT, Jimenez SA. Systemic sclerosis: current views of its pathogenesis [review]. Autoimmun Rev 2003; 2: 18191.
  • 6
    Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004; 140: 3750.
  • 7
    Whiteside TL, Buckingham RB, Prince RK, Rodnan GP. Products of activated mononuclear cells modulate accumulation of collagen by normal dermal and scleroderma fibroblasts in culture. J Lab Clin Med 1984; 104: 35569.
  • 8
    Del Galdo F, Artlett CM. T-cells and B cells in the pathogenesis of systemic sclerosis: recent insights and therapeutic opportunities [review]. Curr Rheumatol Rep 2006; 8: 12330.
  • 9
    Sakkas LI, Chikanza IC, Platsoucas CD. Mechanisms of disease: the role of immune cells in the pathogenesis of systemic sclerosis [review]. Nat Clin Pract Rheumatol 2006; 2: 67985.
  • 10
    Sollberg S, Peltonen J, Uitto J, Jimenez SA. Elevated expression of β1 and β2 integrins, intercellular adhesion molecule 1, and endothelial leukocyte adhesion molecule 1 in the skin of patients with systemic sclerosis of recent onset. Arthritis Rheum 1992; 35: 2908.
  • 11
    Kraling BM, Maul GG, Jimenez SA. Mononuclear cellular infiltrates in clinically involved skin from patients with systemic sclerosis of recent onset predominantly consist of monocytes/macrophages. Pathobiology 1995; 63: 4856.
  • 12
    Sakkas LI, Xu B, Artlett CM, Jimenez SA, Platsoucas CD. Oligoclonal T-cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 364959.
  • 13
    Sakkas LT. New developments in the pathogenesis of systemic sclerosis. Autoimmunity 2005; 38: 1136.
  • 14
    Chizzolini C. Update on pathophysiology of scleroderma with special reference to immunoinflammatory events [review]. Ann Med 2007; 39: 4253.
  • 15
    Johnson RL, Ziff M. Lymphokine stimulation of collagen accumulation. J Clin Invest 1976; 58: 24052.
  • 16
    Jimenez SA, McArthur W, Rosenbloom J. Inhibition of collagen synthesis by mononuclear cell supernates. J Exp Med 1979; 150: 142131.
  • 17
    Atamas SP, Yurovsky VV, Wise R, Wigley FM, Goter Robinson CJ, Henry P, et al. Production of type 2 cytokines by CD8+ lung cells is associated with greater decline in pulmonary function in patients with systemic sclerosis. Arthritis Rheum 1999; 42: 116878.
  • 18
    Kalogerou A, Gelou E, Mountantonakis S, Settas L, Zafiriou E, Sakkas L. Early T-cell activation in the skin from patients with systemic sclerosis. Ann Rheum Dis 2005; 64: 12335.
  • 19
    Distler JH, Jungel A, Caretto D, Schulze-Horsel U, Kowal-Bielecka O, Gay RE, et al. Monocyte chemoattractant protein 1 released from glycosaminoglycans mediates its profibrotic effects in systemic sclerosis via the release of interleukin-4 from T-cells. Arthritis Rheum 2006; 54: 21425.
  • 20
    De Palma R, Del Galdo F, Lupoli S, Altucci P, Abbate G, Valentini G. Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin. Clin Exp Immunol 2006; 144: 16976.
  • 21
    Denton CP, Shi-Wen X, Sutton A, Abraham DJ, Black CM, Pearson JD. Scleroderma fibroblasts promote migration of mononuclear leucocytes across endothelial cell monolayers. Clin Exp Immunol 1998; 114: 293300.
  • 22
    Cipriani P, Milia AF, Liakouli V, Pacini A, Manetti M, Marrelli A, et al. Differential expression of stromal cell–derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: pathogenetic implications. Arthritis Rheum 2006; 54: 302233.
  • 23
    Giacomelli R, Matucci-Cerinic M, Cipriani P, Ghersetich I, Lattanzio R, Pavan A, et al. Circulating Vδ1+ T-cells are activated and accumulate in the skin of systemic sclerosis patients. Arthritis Rheum 1998; 41: 32734.
  • 24
    Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol 2001; 13: 50511.
  • 25
    Distler O, Distler JH, Scheid A, Acker T, Hirth A, Rethage J, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. Circ Res 2004; 95: 10916.
  • 26
    Carulli MT, Ong VH, Ponticos M, Shiwen X, Abraham DJ, Black CM, et al. Chemokine receptor CCR2 expression by systemic sclerosis fibroblasts: evidence for autocrine regulation of myofibroblast differentiation. Arthritis Rheum 2005; 52: 377282.
  • 27
    Del Galdo F, Artlett CM, Jimenez SA. The role of allograft inflammatory factor 1 in systemic sclerosis. Curr Opin Rheumatol 2006; 18: 58893.
  • 28
    Del Galdo F, Maul GG, Jimenez SA, Artlett CM. Expression of allograft inflammatory factor 1 in tissues from patients with systemic sclerosis and in vitro differential expression of its isoforms in response to transforming growth factor β. Arthritis Rheum 2006; 54: 261625.
  • 29
    Utans U, Quist WC, McManus BM, Wilson JE, Arceci RJ, Wallace AF, et al. Allograft inflammatory factory-1: a cytokine-responsive macrophage molecule expressed in transplanted human hearts. Transplantation 1996; 61: 138792.
  • 30
    Utans U, Arceci RJ, Yamashita Y, Russell ME. Cloning and characterization of allograft inflammatory factor-1: a novel macrophage factor identified in rat cardiac allografts with chronic rejection. J Clin Invest 1995; 95: 295462.
  • 31
    Artlett CM, Otieno FG, Cane JR, Jimenez SA. Allograft inflammatory factor 1 gene polymorphisms and tissue expression in systemic sclerosis [abstract]. Arthritis Rheum 2004; 50 Suppl 9: S440.
  • 32
    Alkassab F, Gourh P, Tan FK, McNearney TA, Fischbach M, Ahn C, et al. An allograft inflammatory factor 1 (AIF1) single nucleotide polymorphism (SNP) is associated with anticentromere antibody positive systemic sclerosis [abstract]. Arthritis Rheum 2006; 54 Suppl 9: S732.
  • 33
    Tan FK, Zhou X, Mayes MD, Gourh P, Guo X, Marcum C, et al. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology (Oxford) 2006; 45: 694702.
  • 34
    Roviezzo F, Del Galdo F, Abbate G, Bucci M, D'Agostino B, Antunes E, et al. Human eosinophil chemotaxis and selective in vivo recruitment by sphingosine 1-phosphate. Proc Natl Acad Sci U S A 2004; 101: 111705.
  • 35
    Morrison BE, Park SJ, Mooney JM, Mehrad B. Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 2003; 112: 186270.
  • 36
    Moody MD, van Arsdell SW, Murphy KP, Orencole SF, Burns C. Array-based ELISAs for high-throughput analysis of human cytokines. Biotechniques 2001; 31: 18690, 192–4.
  • 37
    Pennesi G, Mattapallil MJ, Sun SH, Avichezer D, Silver PB, Karabekian Z, et al. A humanized model of experimental autoimmune uveitis in HLA class II transgenic mice. J Clin Invest 2003; 111: 117180.
  • 38
    Klinman D. ELISPOT assay to detect cytokine-secreting murine and human cells. Curr Prot Immunol 1994; 6: 18.
  • 39
    Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, et al. A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: utilization of U937 monocytic cells. J Pharmacol Toxicol Methods 2005; 51: 10514.
  • 40
    Borghi MO, Panzeri P, Shattock R, Sozzani S, Dobrina A, Meroni PL. Interaction between chronically HIV-infected promonocytic cells and human umbilical vein endothelial cells: role of proinflammatory cytokines and chemokines in viral expression modulation. Clin Exp Immunol 2000; 120: 93100.
  • 41
    Kelemen SE, Autieri MV. Expression of allograft inflammatory factor-1 in T lymphocytes: a role in T-lymphocyte activation and proliferative arteriopathies. Am J Pathol 2005; 167: 61926.
  • 42
    Atamas SP, White B. Cytokine regulation of pulmonary fibrosis in scleroderma [review]. Cytokine Growth Factor Rev 2003; 14: 53750.
  • 43
    Pannu J, Gardner H, Shearstone JR, Smith E, Trojanowska M. Increased levels of transforming growth factor β receptor type I and up-regulation of matrix gene program: a model of scleroderma. Arthritis Rheum 2006; 54: 301121.
  • 44
    Shi-Wen X, Chen Y, Denton CP, Eastwood M, Renzoni EA, Bou-Gharios G, et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol Biol Cell 2004; 15: 270719.